Deep-pocketed investors have adopted a bearish approach towards Viking Therapeutics VKTX, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in VKTX usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 9 extraordinary options activities for Viking Therapeutics. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 22% leaning bullish and 77% bearish. Among these notable options, 2 are puts, totaling $53,630, and 7 are calls, amounting to $255,390.
Predicted Price Range
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $45.0 and $65.0 for Viking Therapeutics, spanning the last three months.
Volume & Open Interest Trends
In today's trading context, the average open interest for options of Viking Therapeutics stands at 1159.25, with a total volume reaching 3,361.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Viking Therapeutics, situated within the strike price corridor from $45.0 to $65.0, throughout the last 30 days.
Viking Therapeutics 30-Day Option Volume & Interest Snapshot
Noteworthy Options Activity:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| VKTX | CALL | TRADE | BEARISH | 05/16/25 | $5.4 | $5.1 | $5.2 | $60.00 | $52.0K | 829 | 273 |
| VKTX | CALL | TRADE | BEARISH | 05/16/25 | $5.3 | $5.2 | $5.2 | $60.00 | $52.0K | 829 | 173 |
| VKTX | CALL | TRADE | BEARISH | 01/17/25 | $3.6 | $3.2 | $3.3 | $45.00 | $35.6K | 271 | 280 |
| VKTX | CALL | SWEEP | BEARISH | 01/17/25 | $3.3 | $3.0 | $3.0 | $45.00 | $33.6K | 271 | 822 |
| VKTX | CALL | TRADE | BEARISH | 01/17/25 | $3.5 | $3.1 | $3.1 | $45.00 | $31.0K | 271 | 578 |
About Viking Therapeutics
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
After a thorough review of the options trading surrounding Viking Therapeutics, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
Present Market Standing of Viking Therapeutics
- With a trading volume of 3,362,736, the price of VKTX is down by -9.27%, reaching $42.37.
- Current RSI values indicate that the stock is may be oversold.
- Next earnings report is scheduled for 49 days from now.
Expert Opinions on Viking Therapeutics
In the last month, 5 experts released ratings on this stock with an average target price of $97.8.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access. * An analyst from Piper Sandler has revised its rating downward to Overweight, adjusting the price target to $74. * In a cautious move, an analyst from HC Wainwright & Co. downgraded its rating to Buy, setting a price target of $102. * An analyst from HC Wainwright & Co. downgraded its action to Buy with a price target of $102. * Reflecting concerns, an analyst from B. Riley Securities lowers its rating to Buy with a new price target of $109. * An analyst from HC Wainwright & Co. downgraded its action to Buy with a price target of $102.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Viking Therapeutics options trades with real-time alerts from Benzinga Pro.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
